Leading Innovation|The UK's ATMP Landscape

The Alliance for Regenerative Medicine (ARM) and the BioIndustry Association (BIA) have published a report setting out the scope of the UK’s robust and growing Advanced Therapy Medicinal Products (ATMPs) sector which includes the development of potentially transformative cell and gene therapies.

The report shows that:

• Financings for ATMP companies grew 66% from £473m to £785m between 2017 and 2018 and stand at £347m for 2019 year to date
• More than 70 ATMP developers are active in the UK, including 56 headquartered in the country
• Ninety-three ATMP clinical trials are ongoing in the UK, including 27 sponsored by UK companie